About Bioline  All Journals  Testimonials  Membership  News  Donations

Journal of Cancer Research and Therapeutics
Medknow Publications on behalf of the Association of Radiation Oncologists of India (AROI)
ISSN: 0973-1482
EISSN: 1998-4138
Vol. 6, No. 1, 2010, pp. 58-64
Bioline Code: cr10013
Full paper language: English
Document type: Research Article
Document available free of charge

Journal of Cancer Research and Therapeutics, Vol. 6, No. 1, 2010, pp. 58-64

 en High-dose intensity-modulated radiotherapy as primary therapy for prostate cancer: Report on dosimetry aspects and acute toxicity in the Indian scenario
De, Sandeep; Kannan, Venkatesan; Deshpande, Sudesh; Anand, Vivek & Ghadi, Yogesh


Background and Purpose: Dose escalation improves local control in prostate cancer. In this study we assess the feasibility of dose escalation to prostate and / or seminal vesicles to 76 Gy with intensity-modulated radiotherapy (IMRT); report data on dosimetry and acute toxicity in 40 patients at P. D. Hinduja National Hospital and Medical Research Center, Mumbai.
Materials and Methods: In the period from May 2006 to September 2008, 40 consecutive patients with localized prostate adenocarcinoma (T1- 3 N0) were definitively treated with IMRT to a dose of 76 Gy / 38 fractions. Patients were seen on a weekly basis during treatment, and one month (M1) and three months (M3) thereafter. The radiation therapy oncology group (RTOG) toxicity scale was used to evaluate acute gastrointestinal (GI) and genitourinary (GU) toxicities. Additional symptoms such as rectal blood loss, urgency, dysuria, urinary frequency, nocturia, incontinence were scored as well.
Results: All 40 patients completed treatment successfully. Acute RTOG Grade 1 and Grade 2 GI toxicities were noted in 47.5% (19 patients) and 12.5% (five patients) respectively, leaving 40% (16 patients) free of any acute toxicity. Thirty-six (90%) and four patients (10%) had Grade 0-1 and Grade 2 acute RTOG-scaled GU toxicity respectively. There was no Grade 3 or higher GI / GU toxicity.
Conclusions: The escalated dose of 76 Gy to the prostate with IMRT was very well tolerated by all our patients with acceptable acute GU and GI toxicity, thereby, establishing the feasibility of dose escalation in the Indian scenario.

Prostate cancer, intensity-modulated radiotherapy, dose escalation, acute toxicity

© Copyright 2010 Journal of Cancer Research and Therapeutics.
Alternative site location:

Home Faq Resources Email Bioline
© Bioline International, 1989 - 2022, Site last up-dated on 19-Jan-2022.
Site created and maintained by the Reference Center on Environmental Information, CRIA, Brazil
System hosted by the Internet Data Center of Rede Nacional de Ensino e Pesquisa, RNP, Brazil